



9/2022/AR

Company	LT fundamental recommendation	12M EFV (PLN)	ST market-relative bias	Analyst
<b>BioMaxima</b>	<b>Not rated</b>	<b>37.3</b>	<b>Not rated</b>	Sylvia Jaśkiewicz, CFA +48 571 232 030 Mikołaj Stępień +48 504 949 345

**Event: Preliminary unconsolidated sales for 2021.**

Yesterday, at the beginning of WSE trading, Biomaxima released their preliminary sales for FY21. Unconsolidated sales stand at PLN 78.5 million (+31% yoy). The Company's management informed that FY21 NP should be higher yoy (PLN 7.9 million in FY20). According to our estimates, Biomaxima's consolidated sales and NP in FY21 will reach PLN 79.0 million and PLN 11.1 million, respectively.

**BioMaxima; preliminary FY21 sales**

IFRS (PLN million)	2020 consolidated	2021 unconsolidated	2021E consolidated	2021E vs 2020 chg yoy
Sales	61.3	78.5	79.0	29%
Net income	7.9	n.a.	11.1	40%
Met profit margin	13.0%	-	14.0%	-

Source: Company, DM BOS SA

**Expected impact:** *The information was released during yesterday's trading.*

*The report is not a recommendation within the meaning of Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest.*